Literature DB >> 22772034

Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy.

Ju Hee Ryu1, Heebeom Koo, In-Cheol Sun, Soon Hong Yuk, Kuiwon Choi, Kwangmeyung Kim, Ick Chan Kwon.   

Abstract

Theragnostic nanoparticles (NPs) contain diagnostic and therapeutic functions in one integrated system, enabling diagnosis, therapy, and monitoring of therapeutic response at the same time. For diagnostic function, theragnostic NPs require the inclusion of noninvasive imaging modalities. Among them, optical imaging has various advantages including sensitivity, real-time and convenient use, and non-ionization safety, which make it the leading technique for theragnostic NPs. For therapeutic function, theragnostic NPs have been applied to chemotherapy, photodynamic therapy, siRNA therapy and photothermal therapy. In this review, we present a recent progress reported in the development and applications of theragnostic NPs for cancer therapy. More specifically, we will focus on theragnostic NPs related with optical imaging, highlighting promising strategies based on optical imaging techniques.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772034     DOI: 10.1016/j.addr.2012.06.012

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  35 in total

1.  Clearable Nanoparticles for Cancer Photothermal Therapy.

Authors:  Jun Zhao; Xin Long; Min Zhou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Enabling biodegradable functional biomaterials for the management of neurological disorders.

Authors:  Dingying Shan; Chuying Ma; Jian Yang
Journal:  Adv Drug Deliv Rev       Date:  2019-06-20       Impact factor: 15.470

Review 3.  Recent progress in development and applications of second near-infrared (NIR-II) nanoprobes.

Authors:  Jongyoon Shinn; Sunyoung Lee; Hyon Kyong Lee; Jaeeun Ahn; Seon Ah Lee; Seonju Lee; Yonghyun Lee
Journal:  Arch Pharm Res       Date:  2021-02-04       Impact factor: 4.946

Review 4.  Recent advances in nanoparticle carriers for photodynamic therapy.

Authors:  Gawon Yi; Suk Ho Hong; Jihwan Son; Jihye Yoo; Changhee Park; Yongdoo Choi; Heebeom Koo
Journal:  Quant Imaging Med Surg       Date:  2018-05

Review 5.  Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.

Authors:  Mark Owyong; Niloufar Hosseini-Nassab; Gizem Efe; Alexander Honkala; Renske J E van den Bijgaart; Vicki Plaks; Bryan Ronain Smith
Journal:  Drug Resist Updat       Date:  2017-10-14       Impact factor: 18.500

6.  Ultrasonic assisted green synthesis of Fe and Fe/Zn bimetallic nanoparticles for invitro cytotoxicity study against HeLa cancer cell line.

Authors:  K Sathya; R Saravanathamizhan; G Baskar
Journal:  Mol Biol Rep       Date:  2018-08-20       Impact factor: 2.316

7.  Radionuclide Imaging-Guided Chemo-Radioisotope Synergistic Therapy Using a 131I-Labeled Polydopamine Multifunctional Nanocarrier.

Authors:  Zhiqiang Li; Baikui Wang; Zheng Zhang; Bo Wang; Qiangqiang Xu; Wenjie Mao; Jie Tian; Kai Yang; Fu Wang
Journal:  Mol Ther       Date:  2018-02-24       Impact factor: 11.454

8.  Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances.

Authors:  Richard A Revia; Miqin Zhang
Journal:  Mater Today (Kidlington)       Date:  2016-04       Impact factor: 31.041

9.  Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor.

Authors:  Matthew R Zeiderman; Michael E Egger; Charles W Kimbrough; Christopher G England; Tess V Dupre; Kelly M McMasters; Lacey R McNally
Journal:  J Surg Res       Date:  2014-02-20       Impact factor: 2.192

10.  Preparation of pyrenyl-based multifunctional nanocomposites for biomedical applications.

Authors:  Eun-Kyung Lim; Bong Hyun Chung
Journal:  Nat Protoc       Date:  2016-01-07       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.